Long-Term Effects of Intermittent IL-2 in HIV Infection: Extended Follow-Up of the INSIGHT STALWART Study
Authors:
- Norman MarkowitzNMNorman Markowitz
- STALWART Study GroupSGSTALWART Study Group
Open Access
- 17 October 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e47506
Abstract
The Study of Aldesleukin with and without Antiretroviral Therapy (STALWART) was designed to evaluate whether intermittent IL-2 alone or with peri-cycle ART increased CD4+ cell counts (and so delayed initiation of ART) in HIV infected individuals having ≥300 CD4+ cells/mm3 compared to untreated controls. When the results of two large clinical trials, ESPRIT and SILCAAT, showed no clinical benefit from IL-2 therapy, IL-2 administration was halted in STALWART. Because IL-2 recipients in STALWART experienced a greater number of opportunistic disease (OD) or death and adverse events (AEs), participants were asked to consent to an extended follow-up phase in order to assess persistence of IL-2 effects. Participants in this study were followed for clinical events and AEs every 4 months for 24 months. Unadjusted Cox proportional hazards models were used to summarize death, death or first OD event, and first grade 3 or 4 AE. A total of 267 persons were enrolled in STALWART (176 randomized to the IL-2 arms and 91 to the no therapy arm); 142 individuals in the IL-2 group and 80 controls agreed to enter the extended follow-up study. Initiation of continuous ART was delayed in the IL-2 groups, but once started, resulted in similar CD4+ cell and viral load responses compared to controls. The hazard ratios (95% CI) for IL-2 versus control during the extension phase for death or OD, grade 3 or 4 AE, and grade 4 AE were 1.45 (0.38, 5.45), 0.43 (0.24, 1.63) and 0.20 (0.04, 1.03), respectively. The hazard ratios for the AE outcomes were significantly lower during the extension than during the main study. Adverse events associated with IL-2 cycling did not persist upon discontinuation of IL-2. The use of IL-2 did not impact the subsequent response to initiation of cART.Keywords
This publication has 24 references indexed in Scilit:
- Effects of Intermittent IL-2 Alone or with Peri-Cycle Antiretroviral Therapy in Early HIV Infection: The STALWART StudyPLOS ONE, 2010
- Interleukin-2 Therapy in Patients with HIV InfectionNew England Journal of Medicine, 2009
- Interleukin‐2 before Antiretroviral Therapy in Patients with HIV Infection: A Randomized Trial (ANRS 119)The Journal of Infectious Diseases, 2009
- Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patientsJournal of Antimicrobial Chemotherapy, 2008
- A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK–Vanguard StudyPLoS Clinical Trials, 2006
- Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial)AIDS, 2002
- Impact of immune interventions on proviral HIV‐1 DNA decay in patients receiving highly active antiretroviral therapyHIV Medicine, 2001
- Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4 + and CD8 + T cell turnover in HIV-infected patientsProceedings of the National Academy of Sciences, 2000
- Effects of Intermittent Interleukin‐2 Therapy on Plasma and Tissue Human Immunodeficiency Virus Levels and Quasi‐Species ExpressionThe Journal of Infectious Diseases, 2000
- HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapiesNature Medicine, 1997